NYMOX
Manufacturing · Bahamas · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Bay & Deveaux Sts, Nassau, New Providenc...Phone Number
(800) 936-9669Website
www.nymox.comRevenue
<$5 MillionStock Symbol
NYMXIndustry
About NYMOX
NYMOX Org Chart
Is NYMOX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
NYMOX, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if NYMOX had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at NYMOX
Check if NYMOX has recently received funding, and reach out quickly before it becomes old news!
Check out if NYMOX is spiking on competitors!
Funding: Get notified immidiatlly once NYMOX has new funding data
Earning: See what the market has to say on NYMOX recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when NYMOX launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at NYMOX
Find 2 more new buyers
Company Profile Activity
Activity Insights
NYMOX is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NYMOX is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NYMOX.
NYMOX financials insights
Gather financial insights about NYMOX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Share Placement
$6.4M
NYMOX Tech Stack
A closer look at the technologies used by NYMOX
Most Recent Scoops
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding NYMOX
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasi... Read More